Terms: = Breast cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Clinical Outcome
177 results:
1. MUC1 triggers lineage plasticity of Her2 positive mammary tumors.
Pang Z; Dong X; Deng H; Wang C; Liao X; Liao C; Liao Y; Tian W; Cheng J; Chen G; Yi H; Huang L
Oncogene; 2022 May; 41(22):3064-3078. PubMed ID: 35461328
[TBL] [Abstract] [Full Text] [Related]
2. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract] [Full Text] [Related]
3. Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. clinical outcome and actionable molecular alterations.
Conforti F; Pala L; Pagan E; Rocco EG; Bagnardi V; Montagna E; Peruzzotti G; De Pas T; Fumagalli C; Pileggi S; Pesenti C; Marchini S; Corso G; Marchio' C; Sapino A; Graffeo R; Collet L; Aftimos P; Sotiriou C; Piccart M; Gelber RD; Viale G; Colleoni M; Goldhirsch A
Breast; 2021 Oct; 59():94-101. PubMed ID: 34217971
[TBL] [Abstract] [Full Text] [Related]
4. Patterns of biomarker expression in patients treated with primary endocrine therapy - a unique insight using core needle biopsy tissue microarray.
Parks RM; Albanghali MA; Syed BM; Green AR; Ellis IO; Cheung KL
Breast Cancer Res Treat; 2021 Feb; 185(3):647-655. PubMed ID: 33226492
[TBL] [Abstract] [Full Text] [Related]
5. Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG-TR).
Sakai K; Tsuboi M; Kenmotsu H; Yamanaka T; Takahashi T; Goto K; Daga H; Ohira T; Ueno T; Aoki T; Nakagawa K; Yamazaki K; Hosomi Y; Kawaguchi K; Okumura N; Takiguchi Y; Sekine A; Haruki T; Yamamoto H; Sato Y; Akamatsu H; Seto T; Saeki S; Sugio K; Nishio M; Okabe K; Yamamoto N; Nishio K
Cancer Sci; 2021 Jan; 112(1):388-396. PubMed ID: 33185928
[TBL] [Abstract] [Full Text] [Related]
6. Erlotinib for Non-Small Cell Lung cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101).
Nosaki K; Yamanaka T; Hamada A; Shiraishi Y; Harada T; Himeji D; Kitazaki T; Ebi N; Shimose T; Seto T; Takenoyama M; Sugio K
Oncologist; 2020 Dec; 25(12):e1869-e1878. PubMed ID: 32654250
[TBL] [Abstract] [Full Text] [Related]
7. Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer.
Ryu WJ; Lee JD; Park JC; Cha PH; Cho YH; Kim JY; Sohn JH; Paik S; Choi KY
Exp Mol Med; 2020 May; 52(5):832-842. PubMed ID: 32457491
[TBL] [Abstract] [Full Text] [Related]
8. Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities.
Pancholi S; Ribas R; Simigdala N; Schuster E; Nikitorowicz-Buniak J; Ressa A; Gao Q; Leal MF; Bhamra A; Thornhill A; Morisset L; Montaudon E; Sourd L; Fitzpatrick M; Altelaar M; Johnston SR; Marangoni E; Dowsett M; Martin LA
Oncogene; 2020 Jun; 39(25):4781-4797. PubMed ID: 32307447
[TBL] [Abstract] [Full Text] [Related]
9. Molecular stratification within triple-negative breast cancer subtypes.
Wang DY; Jiang Z; Ben-David Y; Woodgett JR; Zacksenhaus E
Sci Rep; 2019 Dec; 9(1):19107. PubMed ID: 31836816
[TBL] [Abstract] [Full Text] [Related]
10. Efficient Epidermal Growth Factor Receptor Targeting Oligonucleotide as a Potential Molecule for Targeted cancer Therapy.
Wang T; Philippovich S; Mao J; Veedu RN
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31546749
[TBL] [Abstract] [Full Text] [Related]
11. Nuclear erbb-2: a Novel Therapeutic Target in erbb-2-Positive breast cancer?
Cordo Russo RI; Chervo MF; Madera S; Charreau EH; Elizalde PV
Horm Cancer; 2019 Jun; 10(2-3):64-70. PubMed ID: 30656558
[TBL] [Abstract] [Full Text] [Related]
12. clinical Significance of BRAF Non-V600E Mutations in Colorectal cancer: A Retrospective Study of Two Institutions.
Shimada Y; Tajima Y; Nagahashi M; Ichikawa H; Oyanagi H; Okuda S; Takabe K; Wakai T
J Surg Res; 2018 Dec; 232():72-81. PubMed ID: 30463788
[TBL] [Abstract] [Full Text] [Related]
13. Warburg Effect Metabolism Drives Neoplasia in a Drosophila Genetic Model of Epithelial cancer.
Eichenlaub T; Villadsen R; Freitas FCP; Andrejeva D; Aldana BI; Nguyen HT; Petersen OW; Gorodkin J; Herranz H; Cohen SM
Curr Biol; 2018 Oct; 28(20):3220-3228.e6. PubMed ID: 30293715
[TBL] [Abstract] [Full Text] [Related]
14. Role of MEL-18 Amplification in Anti-HER2 Therapy of breast cancer.
Lee JY; Joo HS; Choi HJ; Jin S; Kim HY; Jeong GY; An HW; Park MK; Lee SE; Kim WS; Son T; Min KW; Oh YH; Kong G
J Natl Cancer Inst; 2019 Jun; 111(6):609-619. PubMed ID: 30265336
[TBL] [Abstract] [Full Text] [Related]
15. Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile.
Takahashi S; Thike AA; Koh VCY; Sasano H; Tan PH
Virchows Arch; 2018 Sep; 473(3):275-283. PubMed ID: 30033510
[TBL] [Abstract] [Full Text] [Related]
16. The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer.
Banys-Paluchowski M; Witzel I; Riethdorf S; Pantel K; Rack B; Janni W; Fasching PA; Aktas B; Kasimir-Bauer S; Hartkopf A; Solomayer EF; Fehm T; Müller V
Breast Cancer Res Treat; 2018 Nov; 172(1):93-104. PubMed ID: 30003393
[TBL] [Abstract] [Full Text] [Related]
17. The targeted inhibition of Hsp90 by a synthetic small molecule, DPide offers an effective treatment strategy against TNBCs.
Oh YJ; Park SY; Seo YH
Oncol Rep; 2018 Apr; 39(4):1775-1782. PubMed ID: 29436674
[TBL] [Abstract] [Full Text] [Related]
18. Impact of Concurrent Genomic Alterations Detected by Comprehensive Genomic Sequencing on clinical outcomes in East-Asian Patients with egfr-Mutated Lung Adenocarcinoma.
Sato S; Nagahashi M; Koike T; Ichikawa H; Shimada Y; Watanabe S; Kikuchi T; Takada K; Nakanishi R; Oki E; Okamoto T; Akazawa K; Lyle S; Ling Y; Takabe K; Okuda S; Wakai T; Tsuchida M
Sci Rep; 2018 Jan; 8(1):1005. PubMed ID: 29343775
[TBL] [Abstract] [Full Text] [Related]
19. egfr-targeting PLGA-PEG nanoparticles as a curcumin delivery system for breast cancer therapy.
Jin H; Pi J; Zhao Y; Jiang J; Li T; Zeng X; Yang P; Evans CE; Cai J
Nanoscale; 2017 Nov; 9(42):16365-16374. PubMed ID: 29052674
[TBL] [Abstract] [Full Text] [Related]
20. clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature.
Petrelli F; Tomasello G; Barni S; Lonati V; Passalacqua R; Ghidini M
Breast Cancer Res Treat; 2017 Nov; 166(2):339-349. PubMed ID: 28762010
[TBL] [Abstract] [Full Text] [Related]
[Next]
